ERBB2 and breast carcinoma: A multiregional whole-exome sequencing study in HER2 positive breast cancer revealed that if two biopsies are obtained randomly from a primary breast tumor at diagnosis, more than a quarter of the clonal mutations observed in one biopsy would be absent in the other simply due to the heterogeneity present prior to treatment [99].